Premium
New Pre‐pandemic Influenza Vaccines: An Egg‐ and Adjuvant‐independent Human Adenoviral Vector Strategy Induces Long‐lasting Protective Immune Responses in Mice
Author(s) -
Hoelscher M A,
Jayashankar L,
Garg S,
Veguilla V,
Lu X,
Singh N,
Katz J M,
Mittal S K,
Sambhara S
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100418
Subject(s) - adjuvant , embryonated , immune system , influenza a virus subtype h5n1 , virology , vaccination , pandemic , immunology , influenza vaccine , biology , immunity , viral vector , virus , medicine , covid-19 , infectious disease (medical specialty) , disease , recombinant dna , biochemistry , pathology , gene
Highly pathogenic avian H5N1 influenza viruses that are currently circulating in southeast Asia may acquire the potential to cause the next influenza pandemic. A number of alternate approaches are being pursued to generate cross‐protective, dose‐sparing, safe, and effective vaccines, as traditional vaccine approaches, i.e ., embryonated egg‐grown, are not immunogenic. We developed a replication‐incompetent adenoviral vector‐based, adjuvant‐ and egg‐independent pandemic influenza vaccine strategy as a potential alternative to conventional egg‐derived vaccines. In this paper, we address suboptimal dose and longevity of vaccine‐induced protective immunity and demonstrate that a vaccine dose as little as 1 × 10 6 plaque‐forming unit (PFU) is sufficient to induce protective immune responses against a highly pathogenic H5N1 virus. Furthermore, the vaccine‐induced humoral and cellular immune responses and protective immunity persisted at least for a year. Clinical Pharmacology & Therapeutics (2007) 82 , 665–671. doi: 10.1038/sj.clpt.6100418 ; published online 24 October 2007